<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
  <channel>
    <title>Press Releases - Quantisnow</title>
    <description>Fastest customizable press release feed in the world.</description>
    <link>https://quantisnow.com/news/</link>
    <language>en-us</language>
    <lastBuildDate>Mon, 08 Jun 2026 06:53:01 GMT</lastBuildDate>
    <item>
      <title>Ingredion Announces Recommended All-Cash Acquisition of Tate &amp; Lyle</title>
      <description>Creates a scaled global provider of specialty ingredient solutions for a healthier, tastier and more sustainable future of food Broadens Ingredion&apos;s specialty ingredients platform across texturants, sugar reduction, and fortification, adding complementary capabilities in multi-ingredient systems and recipe developmentExpands Ingredion&apos;s ability to address customer needs across a wider range of end use categories and applicationsBrings together complementary geographic supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific to deliver faster, more reliable and cost-effective ingredients and solutions for customers and consumers worldwide   WESTCHESTER, Ill., </description>
      <link>https://quantisnow.com/insight/ingredion-announces-recommended-all-cash-acquisition-of-tate-lyle-6592331</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/ingredion-announces-recommended-all-cash-acquisition-of-tate-lyle-6592331</guid>
      <pubDate>Mon, 08 Jun 2026 06:20:58 GMT</pubDate>
    </item>
    <item>
      <title>Nebius expands in UK with more NVIDIA-powered infrastructure, more customers, and more cloud capabilities for agentic and enterprise AI</title>
      <description>

Approximately £1.7 billion committed to capacity buildout at four sites



Growing commercial and AI R&amp;D presence at London hub



UK customers using Nebius include pioneers in financial services, healthcare and life sciences



Nebius (NASDAQ:NBIS), the AI cloud company, today announced it is investing approximately £1.7 billion to build out capacity in the UK with three new deployments of NVIDIA infrastructure, as the company continues to expand its commercial and AI R&amp;D hub in London.


Nebius launched its first UK deployment of NVIDIA Blackwell Ultra infrastructure in November 2025. The three new sites will also deploy the latest generations of NVIDIA&apos;s full-stack, end-to-end AI factor</description>
      <link>https://quantisnow.com/insight/nebius-expands-in-uk-with-more-nvidia-powered-infrastructure-more-customers-6592329</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/nebius-expands-in-uk-with-more-nvidia-powered-infrastructure-more-customers-6592329</guid>
      <pubDate>Mon, 08 Jun 2026 06:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Rackspace Technology Establishes Regional Headquarters in Riyadh to Accelerate Cloud and AI Growth</title>
      <description>RIYADH, Saudi Arabia, June  08, 2026  (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ:RXT), a global enterprise AI infrastructure and solutions provider, today announced the establishment of its regional headquarters in Riyadh, Saudi Arabia, reinforcing the company&apos;s long-term commitment to the Kingdom of Saudi Arabia and the broader Middle East region.  The new regional headquarters will serve as a strategic hub for Rackspace Technology&apos;s operations and customer engagement efforts, supporting organizations across enterprise, government, and regulated industries as they accelerate digital transformation initiatives aligned with Saudi Arabia&apos;s Vision 2030 agenda.  The Riyadh office will be </description>
      <link>https://quantisnow.com/insight/rackspace-technology-establishes-regional-headquarters-in-riyadh-to-accelerate-cloud-6592328</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/rackspace-technology-establishes-regional-headquarters-in-riyadh-to-accelerate-cloud-6592328</guid>
      <pubDate>Mon, 08 Jun 2026 05:30:00 GMT</pubDate>
    </item>
    <item>
      <title>WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace</title>
      <description>  WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace  First Quantum Security Service to Launch Within SEALCOIN&apos;s Dedicated Quantum Marketplace, Enabling Organizations to Assess and Prepare for Quantum-Era Cybersecurity Risks  Geneva, Switzerland – June 8, 2026 — WISeKey International Holding Ltd ((SIX: WIHN, NASDAQ:WKEY), a global leader in cybersecurity, digital identity and IoT, today announced the launch of a dedicated Quantum Marketplace within the SEALCOIN platform and the introduction of its flagship application, the QAIT Q-Day Security Assessment Platform. Developed in collaboration with The Hashgraph Group (THG) </description>
      <link>https://quantisnow.com/insight/wisekey-the-hashgraph-group-and-hedera-launch-qait-q-day-security-6592327</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/wisekey-the-hashgraph-group-and-hedera-launch-qait-q-day-security-6592327</guid>
      <pubDate>Mon, 08 Jun 2026 05:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology</title>
      <description>Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche&apos;s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton&apos;s Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors  Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of</description>
      <link>https://quantisnow.com/insight/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-6592326</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/roche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-6592326</guid>
      <pubDate>Mon, 08 Jun 2026 05:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology</title>
      <description>Strategic collaboration combines Nurix&apos;s leadership in targeted protein degradation with Roche&apos;s portfolio of B-cell targeted therapies and global clinical and commercialization footprint  Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies   Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU)  Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto</description>
      <link>https://quantisnow.com/insight/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-6592325</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-6592325</guid>
      <pubDate>Mon, 08 Jun 2026 05:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Digital Realty Launches Malaysia Operations to Advance Southeast Asia&apos;s Digital Connectivity</title>
      <description>  (From left to right) En. Wan Murdani, Senior Vice President, Malaysia Digital Economy Corporation (MDEC); Ms. Zuaida Abdullah, Deputy Chief Executive Officer, Investment Development, Malaysian Investment Development Authority (MIDA); YB Gobind Singh Deo, Minister of Digital; Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty; Billy Lee, Chairman, CSF Advisers Sdn Bhd and Advisor for Malaysia, Digital Realty; and Govind Choudhary, General Manager, Southeast Asia and India, Digital Realty, at the inauguration of Digital Realty&apos;s Malaysia operations in Cyberjaya.   KUALA LUMPUR, Malaysia, June  08, 2026  (GLOBE NEWSWIRE) -- Digital Realty (NYSE:DLR), the world&apos;s largest cl</description>
      <link>https://quantisnow.com/insight/digital-realty-launches-malaysia-operations-to-advance-southeast-asias-digital-6592324</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/digital-realty-launches-malaysia-operations-to-advance-southeast-asias-digital-6592324</guid>
      <pubDate>Mon, 08 Jun 2026 04:46:56 GMT</pubDate>
    </item>
    <item>
      <title>New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales</title>
      <description>Most surveyed technology leaders are accountable for systems they don&apos;t fully controlOnly 11% of respondents say they&apos;re completely prepared for the scale of AI agent deploymentOrganizations that design control into their AI systems achieve significantly stronger performance outcomes.ARMONK, N.Y., June 8, 2026 /CNW/ -- A new IBM (NYSE:IBM) Institute for Business Value study reveals that as AI moves from experimentation to enterprise-wide deployment, two-thirds of surveyed CIOs and CTOs report being held accountable for AI systems they do not fully control, while governance struggles to keep pace at scale.
    
                
                    
                
    
The global study* of 2</description>
      <link>https://quantisnow.com/insight/new-ibm-study-finds-cios-and-ctos-face-growing-ai-6592323</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/new-ibm-study-finds-cios-and-ctos-face-growing-ai-6592323</guid>
      <pubDate>Mon, 08 Jun 2026 04:01:00 GMT</pubDate>
    </item>
    <item>
      <title>Rumble Announces Final Results of Exchange Offer for Northern Data</title>
      <description>Rumble Has Successfully Secured the Support of 85% of Northern Data&apos;s Share Capital  In Total, 46% of Northern Data Shares not subject to Transaction Support Agreements Have Been Tendered  Additional Acceptance Period Expired on June 1, 2026 – Exchange Offer No Longer Open for Acceptance  Closing Expected in mid-June 2026, with application for Delisting of Northern Data Shares expected to be filed immediately Afterwards  Transaction Follows Compelling Strategic Rationale  Longboat Key, FL, June  08, 2026  (GLOBE NEWSWIRE) --  Rumble Inc. (NASDAQ:RUM) (&quot;Rumble&quot;), the Freedom-First technology platform, today announced the final results for its exchange offer to acquire all outstanding shares o</description>
      <link>https://quantisnow.com/insight/rumble-announces-final-results-of-exchange-offer-for-northern-data-6592322</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/rumble-announces-final-results-of-exchange-offer-for-northern-data-6592322</guid>
      <pubDate>Mon, 08 Jun 2026 04:01:00 GMT</pubDate>
    </item>
    <item>
      <title>BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region</title>
      <description>
BitGo MENA FZE (&quot;BitGo MENA&quot;), a subsidiary of BitGo Holdings, Inc. (NYSE:BTGO) (&quot;BitGo&quot;), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA&apos;s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA&apos;s Broker-Dealer license from Dubai&apos;s Virtual Assets Regulatory Authority (VARA).


The launch further expands BitGo MENA&apos;s regulated product suite under VARA&apos;s oversight, marking another step in the region&apos;s continued buildout of institutional d</description>
      <link>https://quantisnow.com/insight/bitgo-mena-launches-regulated-electronic-trading-delivering-full-suite-trading-6592321</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/bitgo-mena-launches-regulated-electronic-trading-delivering-full-suite-trading-6592321</guid>
      <pubDate>Mon, 08 Jun 2026 04:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Solidion Technology Announces $35 Million Private Placement of Common Stock Priced Above Market Under Nasdaq Rules</title>
      <description>Proceeds fully fund the company through 2028 and will be used to accelerate commercialization of Solidion&apos;s patented Extreme-Climate Battery Technology targeting the Lunar economy and space applications  DALLAS, TX, June  07, 2026  (GLOBE NEWSWIRE) --  Solidion Technology Inc. (&quot;Solidion&quot; or the &quot;Company&quot;) (NASDAQ:STI), an advanced battery technology solutions provider, today announced that it has entered into a securities purchase agreement with a new institutional investor for the purchase and sale of 2,333,000 shares of common stock (or common stock equivalents) in a private placement priced above market under Nasdaq rules. The offering is expected to result in gross proceeds of $35 milli</description>
      <link>https://quantisnow.com/insight/solidion-technology-announces-35-million-private-placement-of-common-stock-6592320</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/solidion-technology-announces-35-million-private-placement-of-common-stock-6592320</guid>
      <pubDate>Mon, 08 Jun 2026 01:49:11 GMT</pubDate>
    </item>
    <item>
      <title>Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School</title>
      <description>

FF will hold its FF EAI Robotics Education Ecosystem Strategy, Product Line &amp; New EAI Device Launch at its Los Angeles headquarters on June 16, where the Company will give a full and in-depth introduction to FF&apos;s robotics education ecosystem strategy and also launch its EAI education product line and several major new EAI devices.



On June 22, at Automate in Chicago, the largest robotics show in North America, FF will hold the FF EAI Robotics Multi-Form Lineup Debut &amp; New Product Launch. FF will use this event to share more on its Three-in-One EAI ecosystem and EAI device lineup.



Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) (&quot;Faraday Future&quot;, &quot;FF&quot; or the &quot;Company&quot;), a Califo</description>
      <link>https://quantisnow.com/insight/faraday-future-founder-and-global-ceo-yt-jia-shares-weekly-6592319</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/faraday-future-founder-and-global-ceo-yt-jia-shares-weekly-6592319</guid>
      <pubDate>Sun, 07 Jun 2026 23:30:00 GMT</pubDate>
    </item>
    <item>
      <title>LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China</title>
      <description>SAN DIEGO, June  07, 2026  (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ, &quot;LENZ&quot; or the &quot;Company&quot;)), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or &quot;Everest&quot;), has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (&quot;CORXEL&quot;) to acquire the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region.  Everest Medicines is a biopharmaceutical company focused on discovering, developing</description>
      <link>https://quantisnow.com/insight/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-6592318</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/lenz-therapeutics-announces-everest-medicines-acquired-rights-to-develop-and-6592318</guid>
      <pubDate>Sun, 07 Jun 2026 23:30:00 GMT</pubDate>
    </item>
    <item>
      <title>Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility</title>
      <description>Ramat Gan, Israel, June  07, 2026  (GLOBE NEWSWIRE) -- Odysight.ai® (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company&apos;s financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company&apos;s discretion to support busines</description>
      <link>https://quantisnow.com/insight/odysightai-establishes-at-the-market-atm-program-of-up-to-20-million-6592317</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/odysightai-establishes-at-the-market-atm-program-of-up-to-20-million-6592317</guid>
      <pubDate>Sun, 07 Jun 2026 23:15:00 GMT</pubDate>
    </item>
    <item>
      <title>SK Telecom and NVIDIA Build AI Infrastructure to Power Korea&apos;s AI Innovation</title>
      <description>News Summary:  SK Telecom plans to build a gigawatt-scale AI Cloud in Korea using the NVIDIA DSX platform, with the first AI factory planned to come online in 2027.The AI Cloud will support sovereign, physical and agentic AI services for enterprises and industries across Korea, building on SK Telecom&apos;s network, data center and enterprise infrastructure expertise.NVIDIA DSX will serve as the AI factory architecture blueprint, combining NVIDIA accelerated computing, systems, software and partner technologies to improve time to production and token performance per megawatt.NVIDIA and SK Group are planning to expand their collaboration from AI infrastructure deployments to joint research on next</description>
      <link>https://quantisnow.com/insight/sk-telecom-and-nvidia-build-ai-infrastructure-to-power-koreas-6592316</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/sk-telecom-and-nvidia-build-ai-infrastructure-to-power-koreas-6592316</guid>
      <pubDate>Sun, 07 Jun 2026 23:00:00 GMT</pubDate>
    </item>
    <item>
      <title>NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand</title>
      <description>News Summary:  NAVER, an AI Cloud, will build AI factories on the NVIDIA DSX platform at gigawatt scale, starting with AI infrastructure expansion at GAK Sejong.NVIDIA DSX gives NAVER a proven AI factory blueprint to serve Korea&apos;s industries and global AI cloud customers as demand for useful AI surges at lowest token cost.NAVER will use NVIDIA full-stack AI platforms, models and software to advance regional AI models including next-generation HyperCLOVA X models, its Seoul World Model development and agentic AI services.  SEOUL, South Korea, June  07, 2026  (GLOBE NEWSWIRE) -- NVIDIA and NAVER today announced that NAVER will expand sovereign AI infrastructure, starting at 55 megawatts with p</description>
      <link>https://quantisnow.com/insight/naver-expands-ai-infrastructure-with-nvidia-to-serve-surging-global-6592315</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/naver-expands-ai-infrastructure-with-nvidia-to-serve-surging-global-6592315</guid>
      <pubDate>Sun, 07 Jun 2026 23:00:00 GMT</pubDate>
    </item>
    <item>
      <title>NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories</title>
      <description>News Summary:  NVIDIA and SK hynix announce multiyear technology partnership for next-generation memory aligned to NVIDIA&apos;s AI infrastructure roadmap.The agreement supports supply for advanced memory, addressing the extended development cycles, advanced fabrication and capital investments to sustain the global buildout of AI factories.SK hynix will diversify into new markets NVIDIA is creating — across AI infrastructure, personal AI and physical AI — codeveloping memory for NVIDIA Vera Rubin AI supercomputers, Vera CPUs, RTX Spark-powered PCs and Jetson Thor robotic computing platforms.The two companies will apply AI to semiconductor chip design and manufacturing, using NVIDIA CUDA-X librari</description>
      <link>https://quantisnow.com/insight/nvidia-and-sk-hynix-announce-multiyear-technology-partnership-to-advance-6592314</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/nvidia-and-sk-hynix-announce-multiyear-technology-partnership-to-advance-6592314</guid>
      <pubDate>Sun, 07 Jun 2026 23:00:00 GMT</pubDate>
    </item>
    <item>
      <title>VolitionRx Announces Pricing of $4.6 Million Public Offering</title>
      <description>$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (&quot;Volition&quot;), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. T</description>
      <link>https://quantisnow.com/insight/volitionrx-announces-pricing-of-46-million-public-offering-6592313</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/volitionrx-announces-pricing-of-46-million-public-offering-6592313</guid>
      <pubDate>Sun, 07 Jun 2026 22:30:00 GMT</pubDate>
    </item>
    <item>
      <title>AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS</title>
      <description>VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and e</description>
      <link>https://quantisnow.com/insight/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-6592312</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/amgen-presents-new-data-across-its-cardiometabolic-portfolio-at-american-6592312</guid>
      <pubDate>Sun, 07 Jun 2026 20:45:00 GMT</pubDate>
    </item>
    <item>
      <title>GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders</title>
      <description>Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.  Plans to continue operations without interruption and it is business-as-usual for the Company in providing service for existing Medicare consumers and partners.  CHICAGO, June  07, 2026  (GLOBE NEWSWIRE) -- GoHealth, Inc. (&quot;GoHealth&quot; or the &quot;Company&quot;), a health insurance marketplace and Medicare-focused digital health company, announced that GoHealth and certain of its subsidiaries have voluntarily filed chapter 11 petitions (the</description>
      <link>https://quantisnow.com/insight/gohealth-inc-to-strengthen-its-position-ahead-of-aep-2026-6592311</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/gohealth-inc-to-strengthen-its-position-ahead-of-aep-2026-6592311</guid>
      <pubDate>Sun, 07 Jun 2026 19:40:12 GMT</pubDate>
    </item>
    <item>
      <title>Zealand Pharma announces Boehringer Ingelheim&apos;s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis</title>
      <description>Company announcement No. 21 / 2026  Zealand Pharma announces Boehringer Ingelheim&apos;s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity  News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 ​  Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with </description>
      <link>https://quantisnow.com/insight/zealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-6592310</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/zealand-pharma-announces-boehringer-ingelheims-survodutide-phase-iii-trial-in-6592310</guid>
      <pubDate>Sun, 07 Jun 2026 18:30:00 GMT</pubDate>
    </item>
    <item>
      <title>Lilly&apos;s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause</title>
      <description>In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetesAcross studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic riskINDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced signi</description>
      <link>https://quantisnow.com/insight/lillys-foundayo-orforglipron-the-only-oral-glp-1-taken-without-food-6592309</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/lillys-foundayo-orforglipron-the-only-oral-glp-1-taken-without-food-6592309</guid>
      <pubDate>Sun, 07 Jun 2026 15:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Looney Tunes™ Land Now Open at Six Flags Magic Mountain</title>
      <description>Complete reimagining of the park&apos;s family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney Tunes Land media kit available HERE.LOS ANGELES, June 6, 2026 /PRNewswire/ -- Six Flags Magic Mountain is excited to announce that  Looney Tunes™ Land, a uniquely themed area with loveable characters, is now open. The refreshed family-friendly area has been reimagined where the timeless fun of Looney Tunes™ comes to life. Developed in partnership with Warner Bros. Discovery Global Experiences and designed for young adventurers and families alike, Looney Tunes Land brings together colorful environments, pl</description>
      <link>https://quantisnow.com/insight/looney-tunes-land-now-open-at-six-flags-magic-mountain-6592308</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/looney-tunes-land-now-open-at-six-flags-magic-mountain-6592308</guid>
      <pubDate>Sun, 07 Jun 2026 04:08:00 GMT</pubDate>
    </item>
    <item>
      <title>Duke Energy offers tips to save energy and money as temperatures rise in the Carolinas</title>
      <description>What&apos;s happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperaturesWhy it matters: Acting now with a few simple steps can help reduce energy use during the heat waveCHARLOTTE, N.C., June 6, 2026 /PRNewswire/ -- High temperatures are forecast across the Carolinas this weekend and next week, and Duke Energy has tips to help you take control of your energy use while keeping you and your family cool.
    
                
                    
                
    
Tips to save energy and money Set your thermostat to the highest comfortable setting. Even a couple of degrees can help save energy and money. Keep in </description>
      <link>https://quantisnow.com/insight/duke-energy-offers-tips-to-save-energy-and-money-as-6592307</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/duke-energy-offers-tips-to-save-energy-and-money-as-6592307</guid>
      <pubDate>Sat, 06 Jun 2026 23:05:00 GMT</pubDate>
    </item>
    <item>
      <title>Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems</title>
      <description>Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM&apos;s differentiated approach and high performance   New data expands on findings shared at ATTD and reinforces Eversense 365&apos;s strong patient adherence, glucometrics and hypoglycemic outcomes across an entire year  GERMANTOWN, Md., June  06, 2026  (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announces further data from a large real-world evidence study which reveals </description>
      <link>https://quantisnow.com/insight/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-6592306</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/real-world-evidence-of-eversense-365-presented-at-ada-demonstrating-strong-6592306</guid>
      <pubDate>Sat, 06 Jun 2026 21:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®</title>
      <description>

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association&apos;s (ADA) 86th Scientific Sessions



In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide



Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension



Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stag</description>
      <link>https://quantisnow.com/insight/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-6592305</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-6592305</guid>
      <pubDate>Sat, 06 Jun 2026 20:45:00 GMT</pubDate>
    </item>
    <item>
      <title>Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin</title>
      <description>

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world.



Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1



Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1



DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst</description>
      <link>https://quantisnow.com/insight/dexcom-connect-study-the-most-significant-clinical-study-demonstrating-cgm-6592304</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/dexcom-connect-study-the-most-significant-clinical-study-demonstrating-cgm-6592304</guid>
      <pubDate>Sat, 06 Jun 2026 18:45:00 GMT</pubDate>
    </item>
    <item>
      <title>Lilly&apos;s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications</title>
      <description>In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesityIn addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%)In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1CINDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), tod</description>
      <link>https://quantisnow.com/insight/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-6592303</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-6592303</guid>
      <pubDate>Sat, 06 Jun 2026 18:30:00 GMT</pubDate>
    </item>
    <item>
      <title>All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration</title>
      <description>NEW YORK, June  06, 2026  (GLOBE NEWSWIRE) -- All In FutureTech Alliance (NASDAQ:AIFA) (&quot;AIFA&quot; or the &quot;Company&quot;) today provided a strategic update. Following the Company&apos;s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (&quot;HyalRoute&quot;) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an &quot;AI infrastructure network powered by optical technologies&quot; and an &quot;AI application services matrix.&quot;  The Company stated that, on June 5, AIFA Ch</description>
      <link>https://quantisnow.com/insight/all-in-futuretech-alliance-provides-strategic-updates-hainan-aifa-digital-6592302</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/all-in-futuretech-alliance-provides-strategic-updates-hainan-aifa-digital-6592302</guid>
      <pubDate>Sat, 06 Jun 2026 13:52:17 GMT</pubDate>
    </item>
    <item>
      <title>New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis</title>
      <description>Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association&apos;s (ADA) June 2026 86th Scientific </description>
      <link>https://quantisnow.com/insight/new-abbott-data-show-many-people-with-diabetes-may-not-6592301</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/new-abbott-data-show-many-people-with-diabetes-may-not-6592301</guid>
      <pubDate>Sat, 06 Jun 2026 13:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer&apos;s GLP-1 RA Berobenatide</title>
      <description>

Results from multiple Phase 2b dose finding studies for berobenatide (PF&apos;3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy



VESPER-1 achieved a non-placebo-adjusted weight loss of almost 16% with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide



Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials



Pfizer Inc. (NYSE:PFE) today presented detailed results from multiple Phase 2</description>
      <link>https://quantisnow.com/insight/robust-phase-2b-efficacy-and-favorable-tolerability-support-monthly-dosing-6592300</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/robust-phase-2b-efficacy-and-favorable-tolerability-support-monthly-dosing-6592300</guid>
      <pubDate>Sat, 06 Jun 2026 13:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care</title>
      <description>

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types



EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings



Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet&apos;s technology today—it also fuels </description>
      <link>https://quantisnow.com/insight/insulet-reveals-new-data-supporting-breakthrough-omnipod-6-and-fully-6592299</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/insulet-reveals-new-data-supporting-breakthrough-omnipod-6-and-fully-6592299</guid>
      <pubDate>Sat, 06 Jun 2026 11:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress</title>
      <description>Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978   Deep, dose-dependent B cell depletion observed in peripheral blood and tissue   Favorable safety profile with single target doses up to 30 µg as well as initial multi-dose regimen  Data from the first RA multi-dose regimen cohort and initial clinical data for velinotamig, a BCMAxCD3 T cell engager, to be shared at Cullinan&apos;s Immunology Day on June 10  CAMBRIDGE, Mass., June  06, 2026  (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential firs</description>
      <link>https://quantisnow.com/insight/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-6592298</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-6592298</guid>
      <pubDate>Sat, 06 Jun 2026 09:15:00 GMT</pubDate>
    </item>
    <item>
      <title>Command the Clone Wars&apos;™ Most Cunning Operatives in Star Wars Zero Company™, Launching August 27</title>
      <description>
Watch the Official Gameplay Trailer Showcasing a New Take on Turn-Based Tactics Games; Pre-Orders Now Available for PC, PlayStation 5, Xbox Series X|S


Electronic Arts Inc. (NASDAQ:EA) today announced that Star Wars Zero Company™, a single-player turn-based tactics game, developed by Bit Reactor in collaboration with Lucasfilm Games, will be available on PC, PlayStation® 5 and Xbox Series X|S starting August 27, 2026. Pre-Orders are now available on all platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605316929/en/Star Wars Zero Company Key Art
A new gameplay trailer delivers an action-packed look at the game&apos;s grit</description>
      <link>https://quantisnow.com/insight/command-the-clone-wars-most-cunning-operatives-in-star-wars-6592287</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/command-the-clone-wars-most-cunning-operatives-in-star-wars-6592287</guid>
      <pubDate>Sat, 06 Jun 2026 01:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
      <description>$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants  Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization  ACTON, Mass., June  05, 2026  (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) (&quot;Bluejay&quot; or the &quot;Company&quot;), a medical diagnostics company focused on near-patient testing for critical care, today announced the closing of its previously announced private placement for the purchase </description>
      <link>https://quantisnow.com/insight/bluejay-diagnostics-announces-closing-of-up-to-237-million-private-6592251</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/bluejay-diagnostics-announces-closing-of-up-to-237-million-private-6592251</guid>
      <pubDate>Sat, 06 Jun 2026 00:13:24 GMT</pubDate>
    </item>
    <item>
      <title>Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind&apos;s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems</title>
      <description>Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetesNew data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfactionExploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithmsData from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes  DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June  05, 2026  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic dis</description>
      <link>https://quantisnow.com/insight/data-at-ada-2026-highlights-key-findings-from-clinical-and-6592194</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/data-at-ada-2026-highlights-key-findings-from-clinical-and-6592194</guid>
      <pubDate>Fri, 05 Jun 2026 23:35:00 GMT</pubDate>
    </item>
    <item>
      <title>Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (&quot;ADA&quot;) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study</title>
      <description>•Translational data presented at ADA demonstrate icovamenib&apos;s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist  </description>
      <link>https://quantisnow.com/insight/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-6592189</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-6592189</guid>
      <pubDate>Fri, 05 Jun 2026 23:32:00 GMT</pubDate>
    </item>
    <item>
      <title>Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026</title>
      <description>Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China</description>
      <link>https://quantisnow.com/insight/hengrui-pharma-and-kailera-therapeutics-present-ribupatide-clinical-data-at-6592188</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/hengrui-pharma-and-kailera-therapeutics-present-ribupatide-clinical-data-at-6592188</guid>
      <pubDate>Fri, 05 Jun 2026 23:32:00 GMT</pubDate>
    </item>
    <item>
      <title>Marvell Technology and Flex Set to Join S&amp;P 500; Others to Join S&amp;P MidCap 400 and S&amp;P SmallCap 600</title>
      <description>NEW YORK, June 5, 2026 /PRNewswire/ -- S&amp;P Dow Jones Indices will make the following changes to the S&amp;P 500, S&amp;P MidCap 400, and S&amp;P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&amp;P MidCap 400 and S&amp;P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively. 
Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026</description>
      <link>https://quantisnow.com/insight/marvell-technology-and-flex-set-to-join-sp-500-others-6592184</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/marvell-technology-and-flex-set-to-join-sp-500-others-6592184</guid>
      <pubDate>Fri, 05 Jun 2026 23:25:00 GMT</pubDate>
    </item>
    <item>
      <title>SmartStop Self Storage Named One of Reviewed&apos;s Best National Storage Chains of 2026</title>
      <description>
Highest-Ranked Publicly Traded Self-Storage Company


SmartStop Self Storage REIT, Inc. (&quot;SmartStop&quot;) (NYSE:SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, announced its inclusion in Reviewed&apos;s Best National Storage Chains of 2026. Notably, SmartStop earned the distinction of being the highest-ranked publicly traded self-storage company on this year&apos;s list.


The annual rankings, determined by reader voting, spotlight brands that have earned exceptional consumer trust and satisfaction nationwide. SmartStop&apos;s placement underscores its commitment to providing a superior storage experience, hi</description>
      <link>https://quantisnow.com/insight/smartstop-self-storage-named-one-of-revieweds-best-national-storage-6592152</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/smartstop-self-storage-named-one-of-revieweds-best-national-storage-6592152</guid>
      <pubDate>Fri, 05 Jun 2026 22:50:00 GMT</pubDate>
    </item>
    <item>
      <title>B2Gold Announces Voting Results from its 2026 Annual General and Special Meeting</title>
      <description>VANCOUVER, British Columbia, June  05, 2026  (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX:BTO, NYSE:BTG, NSX: B2G)) (&quot;B2Gold&quot; or the &quot;Company&quot;) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the &quot;Meeting&quot;) held on Thursday, June 4, 2026. A total of 842,480,659 common shares were voted at the Meeting, representing 63.06% of the votes attached to all outstanding common shares.  Shareholders voted overwhelmingly in favor of all items of business before the Meeting. The ten director nominees listed in B2Gold&apos;s Management Information Circular (the &quot;Circular&quot;) dated April 13, 2026, were elected as directors of B2Gold to hold office for the ensuing y</description>
      <link>https://quantisnow.com/insight/b2gold-announces-voting-results-from-its-2026-annual-general-and-6592126</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/b2gold-announces-voting-results-from-its-2026-annual-general-and-6592126</guid>
      <pubDate>Fri, 05 Jun 2026 22:33:21 GMT</pubDate>
    </item>
    <item>
      <title>Western Union Reports Inducement Grants Under New York Stock Exchange Listing Rule 303A.08</title>
      <description>
The Western Union Company (NYSE:WU) today announced that it issued inducement awards to two new non-executive employees under the New York Stock Exchange&apos;s Listing Rule 303A.08.


The awards were granted as restricted stock units (RSUs) with respect to an aggregate of 267,380 shares of the Company&apos;s common stock and were granted as of June 5, 2026. These awards were granted in connection with the employment of certain key employees who will be supporting the execution of the Company&apos;s Beyond strategy, including the Senior Vice President, Global Digital Product and North America Digital Go To Market and the Senior Vice President, Chief Information Security Officer. The RSUs are scheduled to </description>
      <link>https://quantisnow.com/insight/western-union-reports-inducement-grants-under-new-york-stock-exchange-6592093</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/western-union-reports-inducement-grants-under-new-york-stock-exchange-6592093</guid>
      <pubDate>Fri, 05 Jun 2026 22:12:00 GMT</pubDate>
    </item>
    <item>
      <title>Lennar Names Jim Parker Chief Operating Officer and David Grove EVP, Homebuilding</title>
      <description>MIAMI, June 5, 2026 /PRNewswire/ -- Lennar Corporation (NYSE:LEN), one of the nation&apos;s largest homebuilders, today announced that, effective immediately, Jim Parker has been named Chief Operating Officer and David Grove has been named Executive Vice President, Homebuilding.
Mr. Parker and Mr. Grove most recently served as Area Presidents, leading Lennar&apos;s East and West operations, respectively. In their new roles, they will continue to report to Stuart Miller, Executive Chairman, Chief Executive Officer and President of Lennar. Mr. Parker and Mr. Grove each bring 30 years of homebuilding industry experience.Mr. Parker joined Lennar as Regional President through its 2018 merger with CalAtlant</description>
      <link>https://quantisnow.com/insight/lennar-names-jim-parker-chief-operating-officer-and-david-grove-6592062</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/lennar-names-jim-parker-chief-operating-officer-and-david-grove-6592062</guid>
      <pubDate>Fri, 05 Jun 2026 21:56:00 GMT</pubDate>
    </item>
    <item>
      <title>$123 Million Financing Arranged by Marcus &amp; Millichap&apos;s IPA Capital Markets for Bay Area Multifamily Property</title>
      <description>
IPA Capital Markets, a division of Marcus &amp; Millichap (NYSE:MMI) specializing in capital markets services for major private and institutional clients, has secured $123 million in debt financing for a 268-unit luxury multifamily property in Burlingame, California.


Brian Eisendrath, Cameron Chalfant, Anita Paryani-Rice, and Jesse Zarouk of IPA Capital Markets in Los Angeles secured a five-year loan on behalf of a national multifamily owner, operator and investment firm. The loan featured an interest rate of 5.09%, a DSCR of 1.10x, and interest-only payments for the term. The financing structure also included $26 million in preferred equity from Tokyu Land US Corporation.


&quot;Our IPA Capital </description>
      <link>https://quantisnow.com/insight/123-million-financing-arranged-by-marcus-millichaps-ipa-capital-markets-6592039</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/123-million-financing-arranged-by-marcus-millichaps-ipa-capital-markets-6592039</guid>
      <pubDate>Fri, 05 Jun 2026 21:43:00 GMT</pubDate>
    </item>
    <item>
      <title>Perpetua Resources Reports Results of 2026 Annual Meeting</title>
      <description>BOISE, Idaho, June 5, 2026 /CNW/ - Perpetua Resources Corp. (NASDAQ:PPTA) (TSX:PPTA) (&quot;Perpetua Resources&quot; or &quot;Perpetua&quot; or the &quot;Company&quot;) today announced the results of its annual general meeting (the &quot;Annual Meeting&quot;), which was held online through a virtual meeting platform on June 4, 2026.
A total of 100,523,482 common shares were represented at the Annual Meeting, or 80.35% of the votes attached to all outstanding shares at the Company&apos;s record date of April 8, 2026. The Company&apos;s shareholders voted for the election of all director nominees listed in the Company&apos;s management information proxy circular. Detailed results of the vote for the election of directors are as follows: Name of No</description>
      <link>https://quantisnow.com/insight/perpetua-resources-reports-results-of-2026-annual-meeting-6592024</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/perpetua-resources-reports-results-of-2026-annual-meeting-6592024</guid>
      <pubDate>Fri, 05 Jun 2026 21:34:00 GMT</pubDate>
    </item>
    <item>
      <title>Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease in May 2026 of 4.1% Compared to 2025</title>
      <description>GUADALAJARA, Mexico, June  05, 2026  (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE:PAC, BMV:GAP) (&quot;the Company&quot; or &quot;GAP&quot;) announces preliminary terminal passenger traffic figures for May 2026, compared with May 2025.  During May 2026, the 12 Mexican airports operated by GAP recorded a 2.8% decrease in total passenger traffic compared to May 2025. Guadalajara airport reported an increase of 7.1%, while Puerto Vallarta, Tijuana and Los Cabos reported a decrease of 14.4%, 9.8%, and 6.0%, respectively, compared to May 2025. With respect to GAP&apos;s airports in Jamaica, Montego Bay recorded a decrease of 19.1%, while Montego Bay recorded a decrease of 5.2%. Domestic Ter</description>
      <link>https://quantisnow.com/insight/grupo-aeroportuario-del-pacifico-reports-a-passenger-traffic-decrease-in-6591991</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/grupo-aeroportuario-del-pacifico-reports-a-passenger-traffic-decrease-in-6591991</guid>
      <pubDate>Fri, 05 Jun 2026 21:30:31 GMT</pubDate>
    </item>
    <item>
      <title>BIRKS GROUP ANNOUNCES THE CLOSING OF A NEW TERM LOAN FACILITY WITH GORDON BROTHERS REPLACING ITS FORMER TERM LOAN FACILITY AND THE EXTENSION OF ITS REVOLVER FACILITY WITH WELLS FARGO</title>
      <description>All figures presented herein are in Canadian dollars, unless indicated otherwise.MONTREAL, June 5, 2026 /CNW/ - Birks Group Inc. (&quot;Birks Group&quot; or the &quot;Company&quot;) (NYSE American LLC: BGI) announced today the signing of a five-year $32.5 million senior secured term loan facility (&quot;Term Loan&quot;) with 1903P Loan Agent, LLC, an affiliate of Gordon Brothers Group (&quot;Gordon Brothers&quot;) and the designated administrative agent under the facility. The new Term Loan, which matures in June 2031, refinances the Company&apos;s existing $26 million senior secured term loan credit facility which has been repaid in full. Contemporaneously with the closing of the Term Loan with Gordon Brothers, the Company entered int</description>
      <link>https://quantisnow.com/insight/birks-group-announces-the-closing-of-a-new-term-loan-6591782</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/birks-group-announces-the-closing-of-a-new-term-loan-6591782</guid>
      <pubDate>Fri, 05 Jun 2026 21:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Caliber Announces CFO Transition</title>
      <description>SCOTTSDALE, Ariz., June  05, 2026  (GLOBE NEWSWIRE) -- Caliber (NASDAQ:CWD), a diversified real estate and digital asset management platform, today announced that Jade Leung will step down as Chief Financial Officer to pursue a new opportunity, capping an eleven-year tenure during which he built Caliber&apos;s finance organization and helped lead the Company through its initial public offering. Mr. Leung will support an orderly transition. The change is not the result of any disagreement with the Company on any matter relating to its operations, accounting policies, practices, or financial reporting. Caliber reaffirms the full-year 2026 guidance issued on its first quarter 2026 earnings call, and</description>
      <link>https://quantisnow.com/insight/caliber-announces-cfo-transition-6591778</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/caliber-announces-cfo-transition-6591778</guid>
      <pubDate>Fri, 05 Jun 2026 21:00:00 GMT</pubDate>
    </item>
    <item>
      <title>BCB Bancorp, Inc. Announces Inc. Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <description>BAYONNE, N.J., June  05, 2026  (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the &quot;Company&quot;), (NASDAQ:BCBP), the holding company for BCB Community Bank (the &quot;Bank&quot;), today announced that, as previously reported on its Form 8-K filed on June 1, 2026, effective as of the close of trading on June 5, 2026, the Company granted 709,220 shares of restricted common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), to Thomas M. O&apos;Brien as an inducement material to Mr. O&apos;Brien entering into an employment agreement with the Company and commencing employment as its Chief Executive Officer and President. Twenty percent of the shares of restricted stock will vest on each of December 31, 2026, December 31,</description>
      <link>https://quantisnow.com/insight/bcb-bancorp-inc-announces-inc-inducement-grant-under-nasdaq-listing-6591777</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/bcb-bancorp-inc-announces-inc-inducement-grant-under-nasdaq-listing-6591777</guid>
      <pubDate>Fri, 05 Jun 2026 21:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Birks Group Announces the Closing of a New Term Loan Facility With Gordon Brothers Replacing Its Former Term Loan Facility and the Extension of Its Revolver Facility With Wells Fargo</title>
      <description>
All figures presented herein are in Canadian dollars, unless indicated otherwise.


Birks Group Inc. (&quot;Birks Group&quot; or the &quot;Company&quot;) (NYSE American LLC: BGI) announced today the signing of a five-year $32.5 million senior secured term loan facility (&quot;Term Loan&quot;) with 1903P Loan Agent, LLC, an affiliate of Gordon Brothers Group (&quot;Gordon Brothers&quot;) and the designated administrative agent under the facility. The new Term Loan, which matures in June 2031, refinances the Company&apos;s existing $26 million senior secured term loan credit facility which has been repaid in full. Contemporaneously with the closing of the Term Loan with Gordon Brothers, the Company entered into an amendment and extensio</description>
      <link>https://quantisnow.com/insight/birks-group-announces-the-closing-of-a-new-term-loan-6591776</link>
      <guid isPermaLink="true">https://quantisnow.com/insight/birks-group-announces-the-closing-of-a-new-term-loan-6591776</guid>
      <pubDate>Fri, 05 Jun 2026 21:00:00 GMT</pubDate>
    </item>
  </channel>
</rss>